The White House, under pressure to do more to address the global coronavirus pandemic, announced Thursday that it will invest nearly $3 billion to ramp up domestic production of critical vaccine components as part of President Biden’s push to make the United States the “arsenal of vaccines for the world.”
The money, $2.7 billion, will go to firms doing business in the United States that make supplies necessary for vaccine production, including lipids, bioreactor bags, tubing, needles and syringes, officials said. It will come from funds appropriated by Congress through the American Rescue Plan, the $1.9 trillion economic stimulus package Mr. Biden signed into law in March.
“This new investment will further expand domestic vaccine manufacturing capacity, helping the U.S. deliver on its commitment to be the arsenal of vaccines for the world and preparing America for future vaccination efforts,” said Jeffrey D. Zients, Mr. Biden’s coronavirus response coordinator, who announced the effort during a briefing with reporters.
Details, however, were scant. The Department of Health and Human Services is in the “final stages” of awarding contracts for the work, and will make announcements in the coming weeks, according to a White House official who was not authorized to speak publicly about the investment. Neither the official or Mr. Zients could provide an estimate of how many doses the investment would yield.